Biomolecules & Therapeutics

  • 제29권3호
  • /
  • Pages.268-272
  • /
  • 2021
  • /
  • 1976-9148(pISSN)
  • /
  • 2005-4483(eISSN)
한국응용약물학회 (The Korean Society of Applied Pharmacology)
권호 표지
DOI QR코드

DOI QR Code

Antiviral Efficacy of Pralatrexate against SARS-CoV-2

  • Bae, Joon-Yong (Department of Microbiology, Institute for Viral Diseases, Korea University College of Medicine) ;
  • Lee, Gee Eun (Department of Microbiology, Institute for Viral Diseases, Korea University College of Medicine) ;
  • Park, Heedo (Department of Microbiology, Institute for Viral Diseases, Korea University College of Medicine) ;
  • Cho, Juyoung (Department of Microbiology, Institute for Viral Diseases, Korea University College of Medicine) ;
  • Kim, Jeonghun (Department of Microbiology, Institute for Viral Diseases, Korea University College of Medicine) ;
  • Lee, Jungmin (Department of Microbiology, Institute for Viral Diseases, Korea University College of Medicine) ;
  • Kim, Kisoon (Department of Microbiology, Institute for Viral Diseases, Korea University College of Medicine) ;
  • Kim, Jin Il (Department of Microbiology, Institute for Viral Diseases, Korea University College of Medicine) ;
  • Park, Man-Seong (Department of Microbiology, Institute for Viral Diseases, Korea University College of Medicine)
  • 투고 : 2021.02.08
  • 심사 : 2021.03.01
  • 발행 : 2021.05.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Novel coronavirus (SARS-CoV-2) has caused more than 100 million confirmed cases of human infectious disease (COVID-19) since December 2019 to paralyze our global community. However, only limited access has been allowed to COVID-19 vaccines and antiviral treatment options. Here, we report the efficacy of the anticancer drug pralatrexate against SARS-CoV-2. In Vero and human lung epithelial Calu-3 cells, pralatrexate reduced viral RNA copies of SARS-CoV-2 without detectable cytotoxicity, and viral replication was successfully inhibited in a dose-dependent manner. In a time-to-addition assay, pralatrexate treatment at almost half a day after infection also exhibited inhibitory effects on the replication of SARS-CoV-2 in Calu-3 cells. Taken together, these results suggest the potential of pralatrexate as a drug repurposing COVID-19 remedy.

키워드

참고문헌

  1. Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., Lopez de Castilla, D., Finberg, R. W., Dierberg, K., Tapson, V., Hsieh, L., Patterson, T. F., Paredes, R., Sweeney, D. A., Short, W. R., Touloumi, G., Lye, D. C., Ohmagari, N., Oh, M. D., Ruiz-Palacios, G. M., Benfield, T., Fatkenheuer, G., Kortepeter, M. G., Atmar, R. L., Creech, C. B., Lundgren, J., Babiker, A. G., Pett, S., Neaton, J. D., Burgess, T. H., Bonnett, T., Green, M., Makowski, M., Osinusi, A., Nayak, S. and Lane, H. C.; ACTT-1 Study Group Members (2020) Remdesivir for the treatment of Covid-19 - final report. N. Engl. J. Med. 383, 1813-1826. https://doi.org/10.1056/NEJMoa2007764
  2. CDC (2021a) COVID Data Tracker. COVID-19 Vaccinations in the United States. Centers for Disease Control and Prevention. Available from: https://covid.cdc.gov/covid-data-tracker/#vaccinations/ [accessed 2021 Jan 31].
  3. CDC (2021b) COVID Data Tracker. United States COVID-19 Cases and Deaths by State. Centers for Disease Control and Prevention. Available from: https://covid.cdc.gov/covid-data-tracker/#cases_casesinlast7days/ [accessed 2021 Jan 31].
  4. CDC (2021c) Different COVID-19 Vaccines. Centers for Disease Control and Prevention. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines.html/ [accessed 2021 Jan 15].
  5. Corman, V. M., Landt, O., Kaiser, M., Molenkamp, R., Meijer, A., Chu, D. K., Bleicker, T., Brunink, S., Schneider, J., Schmidt, M. L., Mulders, D. G., Haagmans, B. L., van der Veer, B., van den Brink, S., Wijsman, L., Goderski, G., Romette, J. L., Ellis, J., Zambon, M., Peiris, M., Goossens, H., Reusken, C., Koopmans, M. P. and Drosten, C. (2020) Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 25, 2000045.
  6. Drugbank (2021) Pralatrexate. Accession number: DB06813. Available from: https://go.drugbank.com/drugs/DB06813/ [created 2010 Sep 14; updated 2021 Feb 04].
  7. ECDC (2021) COVID-19 Situation Update for the EU/EEA, as of Week 3. European Centre for Disease Prevention and Control. Available from: https://www.ecdc.europa.eu/en/cases-2019-ncov-eueea/ [updated 2021 Jan 28].
  8. FDA (2020) COVID-19 Treatment Guidelines. Antiviral Drugs That Are Approved or Under Evaluation for the Treatment of COVID-19. U.S. Food and Drug Administration. Available from: https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/ [last updated 2020 Nov 3].
  9. Hong, J. Y., Yoon, D. H., Yoon, S. E., Kim, S. J., Lee, H. S., Eom, H. S., Lee, H. W., Shin, D. Y., Koh, Y., Yoon, S. S., Jo, J. C., Kim, J. S., Kim, S. J., Cho, S. H., Lee, W. S., Won, J. H., Kim, W. S. and Suh, C. (2019) Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis. Sci. Rep. 9, 20302. https://doi.org/10.1038/s41598-019-56891-0
  10. Jones, L., Palumbo, D. and Brown, D. (2021) Coronavirus: How the Pandemic Has Changed the World Economy. BBC News. Available from: https://www.bbc.com/news/business-51706225/ [2021 Jan 24].
  11. Kim, J. I., Lee, S., Lee, G. Y., Park, S., Bae, J. Y., Heo, J., Kim, H. Y., Woo, S. H., Lee, H. U., Ahn, C. A., Bang, H. J., Ju, H. S., Ok, K., Byun, Y., Cho, D. J., Shin, J. S., Kim, D. Y., Park, M. S. and Park, M. S. (2019) Novel small molecule targeting the hemagglutinin stalk of influenza viruses. J. Virol. 93, e00878-19.
  12. The Lancet (2020) COVID-19: the worst may be yet to come. Lancet 396, 71. https://doi.org/10.1016/s0140-6736(20)31517-8
  13. Van Lancker, W. and Parolin, Z. (2020) COVID-19, school closures, and child poverty: a social crisis in the making. Lancet Public Health 5, e243-e244.
  14. WHO (2020a) WHO Coronavirus Disease (COVID-19) Dashboard. World Health Organization. Available from: https://covid19.who.int/ [accessed 2021 Jan 31].
  15. WHO (2020b) COVID-19 Studies from the WHO Database. World Health Organization's International Clinical Trials Registry Platform (WHO ICTRP). Available from: https://clinicaltrials.gov/ct2/who_table/ [accessed 2020 May 19].
  16. WHO (2021a) "Solidarity" Clinical Trial for COVID-19 Treatments. Latest Update on Treatment Arms. World Health Organization. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments/.
  17. WHO (2021b) Draft Landscape and Tracker of COVID-19 Candidate Vaccines. World Health Organization. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines/ [accessed 2021 Jan 26].
  18. WHO Solidarity Trial Consortium, Pan, H., Peto, R., Henao-Restrepo, A. M., Preziosi, M. P., Sathiyamoorthy, V., Abdool Karim, Q., Alejandria, M. M., Hernandez Garcia, C., Kieny, M. P., Malekzadeh, R., Murthy, S., Reddy, K. S., Roses Periago, M., Abi Hanna, P., Ader, F., Al-Bader, A. M., Alhasawi, A., Allum, E., Alotaibi, A., AlvarezMoreno, C. A., Appadoo, S., Asiri, A., Aukrust, P., Barratt-Due, A., Bellani, S., Branca, M., Cappel-Porter, H. B. C., Cerrato, N., Chow, T. S., Como, N., Eustace, J., Garcia, P. J., Godbole, S., Gotuzzo, E., Griskevicius, L., Hamra, R., Hassan, M., Hassany, M., Hutton, D., Irmansyah, I., Jancoriene, L., Kirwan, J., Kumar, S., Lennon, P., Lopardo, G., Lydon, P., Magrini, N., Maguire, T., Manevska, S., Manuel, O., McGinty, S., Medina, M. T., Mesa Rubio, M. L., Miranda-Montoya, M. C., Nel, J., Nunes, E. P., Perola, M., Portoles, A., Rasmin, M. R., Raza, A., Rees, H., Reges, P. P. S., Rogers, C. A., Salami, K., Salvadori, M. I., Sinani, N., Sterne, J. A. C., Stevanovikj, M., Tacconelli, E., Tikkinen, K. A. O., Trelle, S., Zaid, H., Rottingen, J. A. and Swaminathan, S. (2020) Repurposed antiviral drugs for Covid-19 - interim WHO Solidarity trial results. N. Engl. J. Med. 384, 497-511. https://doi.org/10.1056/NEJMoa2023184
  19. Zhang, H., Yang, Y., Li, J., Wang, M., Saravanan, K. M., Wei, J., Tze-Yang Ng, J., Tofazzal Hossain, M., Liu, M., Zhang, H., Ren, X., Pan, Y., Peng, Y., Shi, Y., Wan, X., Liu, Y. and Wei, Y. (2020) A novel virtual screening procedure identifies Pralatrexate as inhibitor of SARS-CoV-2 RdRp and it reduces viral replication in vitro. PLoS Comput. Biol. 16, e1008489. https://doi.org/10.1371/journal.pcbi.1008489